Publikationen der ALS-Forschungsgruppe an der Charité
Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme
Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J,
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spastic using tetrahydrocannabinol:cannabidiol (THC:CBD)
Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B,
Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, Münch C,
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S,
Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Kettemann D, Funke A, Maier A, Rosseau S, Meyer R, Spittel S,
Interleukin-1 Antagonist Anakinra in Amyotriphic Lateral Sclerosis – A Pilot Study
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS)
Janssens AI, Ruytings M, Al-Chalabi A,
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
Vercruysse P, Sinniger J, El Oussini
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia
Freischmidt A, Wieland T, Richter B,
Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study
Dorst J, Dupuis L, Petri S,
A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity
Joyce PI, Mcgoldrick P, Saccon RA,
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression
Küffner R, Zach N, Norel R,
Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study
van Doormaal PT, Ticozzi N, Gellera
A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis
Lenglet T, Lacomblez L, Abitbol JL,
Live and let die: existential decision processes in a fatal disease
Lulé D, Nonnenmacher S, Sorg S,
In vivo waveguide elastography: effects of neurodegeneration in patients with amyotrophic lateral sclerosis
Romano A, Guo J, Prokscha T, Meyer
